BUZZ Investing: April Rebound Calms a March Washout>

Why It Matters

The performance gap underscores the volatility of socially‑driven AI themes and highlights emerging investor appetite for biotech and crypto exposures within thematic funds.

Key Takeaways

• BUZZ Index down 11.2% YTD, lagging S&P 500's -4.3%.
• April rebound lifted S&P 500 and Nasdaq 2.4% each.
• Nebius, Intel, AMD drove gains on AI infrastructure demand.
• Super Micro fell after export‑control charges; Hims hit by GLP‑1 concerns.
• ImmunityBio and four crypto stocks added, signaling broader sentiment shift.

Pulse Analysis

The BUZZ Index’s sharp decline through March mirrored a broader risk‑off environment driven by the U.S.–Israel‑Iran standoff, elevated energy prices, and a cautious Federal Reserve holding rates at the 3.75% upper bound. While the S&P 500 and Nasdaq managed to swing back into positive territory in early April, the BUZZ Index lagged, reflecting its concentration in higher‑beta AI and growth stocks that were hit hardest during the sell‑off. This divergence highlights the sensitivity of thematic, sentiment‑based ETFs to macro‑level shocks, especially when their constituents are tied to emerging technologies with volatile earnings profiles.

The rebound in early April was anchored by a resurgence in AI infrastructure spending, benefitting Nebius, Intel and AMD. Nebius secured a $27 billion AI compute deal with Meta and announced a 310‑MW data center in Finland, reinforcing its position as a European AI hub. Intel’s strategic moves—including a stake repurchase in its Irish fab, participation in Elon Musk’s Terafab project, and an expanded Google partnership—bolstered confidence, while AMD’s deeper ties with Samsung on AI memory underscored its role in the high‑performance computing supply chain. Conversely, Super Micro’s stock tumbled after U.S. prosecutors charged its co‑founder over alleged export‑control violations, and Hims & Hers faced margin pressure as its GLP‑1 weight‑loss franchise transitions to higher‑cost branded products.

April’s index rebalance signals a widening of sentiment beyond pure AI themes. ImmunityBio, riding a wave of social media buzz around its ANKTIVA bladder‑cancer therapy, entered at the full 3% weight, illustrating how biotech narratives can quickly permeate thematic funds. Simultaneously, four crypto‑related equities—CRCL, TeraWulf, BitMine Immersion, and Galaxy Digital—joined the basket, reflecting renewed optimism in digital‑asset exposure despite broader crypto price weakness. For investors, these additions suggest a diversification of thematic risk, blending AI infrastructure, biotech breakthroughs, and crypto sentiment, and may foreshadow a more resilient performance trajectory if macro pressures ease.